Latest uveitis Stories

2014-08-12 16:25:27

LONDON, Aug. 12, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Uveitis Market 2014-2018.pdfhttps://www.reportbuyer.com/product/2170336/Global-Uveitis-Market-2014-2018pdf.htmlAbout UveitisUveitis is defined as the inflammation of the middle layer of the eye i.e. the uvea, also known as the uceal tract. The uvea consists of the iris, choroid and ciliary body. Infections, injury and autoimmune disorders may be related with the development of uveitis;...

2014-06-20 23:03:00

Global Uveitis Market 2014-2018, a new research report available at ReportsnReports.com. Dallas, Texas (PRWEB) June 20, 2014 Currently, the current competition in the Global Uveitis market is weak and the available treatment options have only been moderately successful in meeting market demand. The current market is served in the main by three approved products, namely Alcon Laboratories' Durezol, Allergan's Ozurdex, and Bausch & Lomb's Retisert. The expected entry of new...

2014-05-20 16:26:30

NORTH CHICAGO, Ill., May 20, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration (FDA) has granted HUMIRA(®) (adalimumab) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye. AbbVie is investigating the efficacy and safety of HUMIRA for the treatment of non-infectious uveitis, and the clinical...

2014-01-22 12:27:27

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: EpiCast Report: Uveitis - Epidemiology Forecast to 2022 EpiCast Report: Uveitis - Epidemiology Forecast to 2022 Summary Uveitis is a serious eye condition that often results in permanent vision damage due to frequent recurrence even after treatment. It consists of a group of diseases that present with inflammation of the uvea, can occur in one or both eyes, and may also affect the...

2013-12-31 08:22:44

PETACH TIKVA, Israel, Dec. 31, 2013 /PRNewswire/ -- OphthaliX Inc. (OTCQB: OPLI), announced today that it will conduct a retrospective analysis of the Phase III Dry Eye Syndrome study data to determine if there is a correlation between the CF101 target, the A3 adenosine receptor, expression and patients' response to the drug. This analysis is based on recent positive data from a Phase IIb Rheumatoid Arthritis study of CF101 conducted by OphthaliX's parent company, Can-Fite BioPharma...

Word of the Day
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'